Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.…

Massive Investment in US Manufacturing Triggers Wave of Career Opportunities

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and…

Tempus AI: Deal mit Pharma-Riesen – Aktie geht steil

Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig…

Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The companys…

Why Tempus AI Stock Is Skyrocketing Today

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain…

Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop…

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.…

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers…

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trumps trade policies. The 47th U.S. president decided to impose steep tariffs…

Astrazeneca Aktie: Details zum strategischen Plan

Trotz aktueller Schwächephase halten Analysten an Kaufempfehlungen fest - Dividendenankündigung und Quartalszahlen im Fokus. Die AstraZeneca-Aktie zeigt sich diese Woche…

The Zacks Analyst Blog AbbVies, Rinvoq and AstraZenecas and Novartis

AbbVies, Rinvoq and AstraZenecas and Novartis are included in this Analyst Blog.…

Result of AGM

11 April 2025 Results of Annual General Meeting held on 11 April 2025 AstraZeneca PLC announced the results of the voting at…

Gothenburg - a launch pad for health innovators

As the Nordic region’s largest healthcare market and a leading life science nation, Sweden is an attractive environment for healthtech…

Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs

The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly…

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today

Might the tariff risk for pharmaceutical stocks be less than you think?…

3 No-Brainer Growth Stocks to Buy for Less Than $100

Dont let the sell-off in the markets scare you off: Now may be an ideal time to buy stocks. Even…

Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $64.90, representing a -1.35% change from its previous close.…

AstraZenecas Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy

…

AstraZenecas metastatic breast cancer treatment gets EU nod

…

Imfinzi approved in EU for AEGEAN

04 April 2025 Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer  Approval based on AEGEAN Phase III trial…

Enhertu approved in EU in post-ET breast cancer

04 April 2025 Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer…

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Markets Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the…

UK pharma escapes worst of Trump tariffs (for now) but uncertainty may keep pressure on shares

International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump’s sweeping new tariff...…

AstraZeneca and GSK shares rise on possible escape from new US tariffs

UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that...…

Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up

AstraZenecas new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.…

Calquence recommended for EU approval in 1L MCL

31 March 2025 Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line…

Imfinzi approved in the US for bladder cancer

31 March 2025 Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer  Based on NIAGARA Phase III…

AstraZenecas Imfinzi gains additional indication for bladder cancer

…

2 Surefire Dividend Stocks That Could Pay You for Life

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust…

Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street…

Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.…

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly…

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Pharmaceutical company will invest money over five years in ‘strategic partnership’ with the city’s authorities…

Astrazeneca Aktie: Marktbewegung vorausgesehen?

Der britische Pharmakonzern baut seine Präsenz im chinesischen Markt mit einem 2,5-Milliarden-Dollar Forschungszentrum in Peking aus, was Anleger vorerst skeptisch…

AstraZeneca details $2.5B investment in Chinas political center, funding R&D center, biotech pacts

AstraZeneca has shown its commitment to China amid investigations into its executives and activities,…

AstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probes

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the…

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals By Reuters

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals…

British pharma giant AstraZeneca to invest $2.5 billion in new China hub

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing,…

AstraZeneca to invest $2.5 billion in new Beijing R&D center By Investing.com

AstraZeneca to invest $2.5 billion in new Beijing R&D center…

AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…

ANGLE passes key milestone as it completes AstraZeneca assay development

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.…

Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential By Investing.com

Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential…

AZNs Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer

The European Commission approves AstraZenecas Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.…

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or…

European stocks rise on German debt deal hopes; AstraZeneca in focus By Investing.com

European stocks rise on German debt deal hopes; AstraZeneca in focus…

AstraZeneca to acquire EsoBiotec advance cell therapy platform

AstraZeneca has announced an agreement to acquire EsoBiotec, securing the biotechnology firm’s pioneering in vivo cell therapy platform that has…

AstraZeneca to buy EsoBiotec for up to $1 billion

Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion.…

Prediction: This Vanguard Index Fund Will Continue to Beat the S&P 500 in 2025

The Trump administration has unnerved investors with its departure from traditional trade policy. The average tax on U.S. imports fell…